An approach for the enantioselective synthesis of biologically active furanones from a Morita–Baylis–Hillman adduct
摘要:
Herein, we disclose an approach for the asymmetric synthesis of both enantiomers of an anti-inflammatory furanone. The approach is based on the utilization of a Morita-Baylis-Hillman adduct as starting material and has as key step a selective epoxide-opening/benzylic oxidation mediated by Palladium (II). This sequence afforded an advanced intermediate, which was used to accomplish the total synthesis. Experimental evidences allowed us to suggest a mechanistic proposal for the oxidation Palladium(II)-mediated. (C) 2010 Elsevier Ltd. All rights reserved.
An approach for the enantioselective synthesis of biologically active furanones from a Morita–Baylis–Hillman adduct
摘要:
Herein, we disclose an approach for the asymmetric synthesis of both enantiomers of an anti-inflammatory furanone. The approach is based on the utilization of a Morita-Baylis-Hillman adduct as starting material and has as key step a selective epoxide-opening/benzylic oxidation mediated by Palladium (II). This sequence afforded an advanced intermediate, which was used to accomplish the total synthesis. Experimental evidences allowed us to suggest a mechanistic proposal for the oxidation Palladium(II)-mediated. (C) 2010 Elsevier Ltd. All rights reserved.
(Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
申请人:Merck Frosst Canada, Inc.
公开号:US06020343A1
公开(公告)日:2000-02-01
The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
This invention encompasses a process for making a compound of Formula A
1
These compounds are intermediates useful in the preparation of certain non-steroidal anti-inflammatory agents.